TANYA LEWIS: Open Payments
NPI 1831304583 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,218 in 71 payments from 15 companies in 2025. Trend: 2023 $1,049 · 2024 $1,038 · 2025 $1,218
Food & beverage: $1,218
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 17 | $274 |
| Otsuka America Pharmaceutical, Inc. | 10 | $183 |
| Alkermes, Inc. | 8 | $144 |
| Janssen Pharmaceuticals, Inc | 7 | $126 |
| Teva Pharmaceuticals USA, Inc. | 7 | $117 |
| Luye Pharma (USA) Ltd. | 4 | $77 |
| Supernus Pharmaceuticals, Inc. | 5 | $77 |
| E.R. Squibb & Sons, L.L.C. | 3 | $73 |
| Lundbeck LLC | 2 | $39 |
| Almatica Pharma LLC | 2 | $31 |
Products named: INGREZZA, REXULTI, ARISTADA, INVEGA SUSTENNA, ERZOFRI EXTENDED-RELEASE, Qelbree, UZEDY, COBENFY.
Industry payments across NY — which companies pay providers there.
